株式会社極東書店トップ商品一覧Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials.

商品詳細

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials.

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials.

・ISBN 978-1-032-11129-2 hard GB£ 145.99

¥46,249.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り
電子版あり 大学・学術機関向け電子ブック(eBook)ISBN 9781003218531
著者・編者Grieve, Andrew P.,
シリーズ (Chapman & Hall/CRC Biostatistics Series)
出版社 (Chapman & Hall/CRC, UK)
出版年月2022
ページ数188 pp.
言語ENG
ニュース番号<A01-50674>

解説

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials provides a practical introduction to unconditional approaches to planning randomised clinical trials, particularly aimed at drug development in the pharmaceutical industry. This book is aimed at providing guidance to practitioners in using average power, assurance and related concepts. This book brings together recent research and sets them in a consistent framework and provides a fresh insight into how such methods can be used.

Features:

  • A focus on normal theory linking average power, expected power, predictive power, assurance, conditional Bayesian power and Bayesian power.
  • Extensions of the concepts to binomial, and time-to-event outcomes and non-inferiority trials
  • An investigation into the upper bound on average power, assurance and Bayesian power based on the prior probability of a positive treatment effect
  • Application of assurance to a series of trials in a development program and an introduction of the assurance of an individual trial conditional on the positive outcome of an earlier trial in the program, or to the successful outcome of an interim analysis
  • Prior distribution of power and sample size
  • Extension of the basic approach to proof-of-concept trials with dual success criteria
  • Investigation of the connection between conditional and predictive power at an interim analysis and power and assurance
  • Introduction of the idea of surety in sample sizing of clinical trials based on the width of the confidence intervals for the treatment effect, and an unconditional version.